High dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections

摘要: Background Helicobacter pylori infections have become increasingly difficult to treat. Aim To examine whether amoxicillin and high-dose dexlansoprazole would reliably achieve an H. pylori eradication rate of ≥90%. Methods An open-label prospective pilot study in treatment-naive subjects with active infection (positive by two tests). Therapy: 1 g 120 mg each twice a day at approximately 12-hour intervals for 14 days. Success was accessed urea breath test. An effective therapy defined as per-protocol treatment success 90% or greater; 80% less prespecified unacceptable result. Results After 13 were entered (12 men, one woman; average age 54 years), the stopping rule six failures achieved (i.e., 95% confidence interval excluded achieving required even if proposed 50 completed patients entered) enrollment stopped. Per-protocol intention-to-treat both 53.8%; (7/13); CI = 25–80%. Compliance 100%. Three (23%) reported side effects, all which mild none interrupted therapy. Conclusion Theoretically, dual PPI plus should eradicate provided nearly neutral intragastric pH can be maintained. Clearly, dexlansoprazole, despite being administered high dose total daily 240 mg), failed milieu consistent anti-H. pylori regimen.